Loading clinical trials...
Loading clinical trials...
Real World Evidence Clinical Utility Study of KidneyIntelX in Patients With Type 2 Diabetes and Chronic Kidney Disease
The purpose of this study is to assess the impact of the KidneyIntelX assay utilized as part of the current standard of care on the management of patients seen in the primary care physician's office at Mount Sinai.
Age
23 - No limit years
Sex
ALL
Healthy Volunteers
No
Mount Sinai Health System
New York, New York, United States
Start Date
March 2, 2021
Primary Completion Date
December 2, 2024
Completion Date
December 1, 2026
Last Updated
April 12, 2024
10,000
ESTIMATED participants
KidneyIntelX
DIAGNOSTIC_TEST
Lead Sponsor
Renalytix AI, Inc.
Collaborators
NCT07271186
NCT04592640
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07094906